This is a preview of subscription content, log in via an institution to check access.
References
Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis 1983;147:1090–1098.
Fischer GW, Hunter KW, Hemming VG, Wilson SR. Functional antibacterial activity of a human intravenous immunoglobulin preparation: in vitro and in vivo studies. Vox Sang 1983;44:296–299.
Dalhoff A. In vitro and in vivo effect of immunoglobulin G on the integrity of bacterial membranes. Infection 1985;13(Suppl 2):S185–S191.
Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990;71:372–376.
Horiuchi A, Abe Y, Miyake M, Osuka Y, Kimura S. Natural human IgG inhibits the production of tumor necrosis factor and interleukin-1 alpha through the Fc portion. Surgery Today 1993;23:241–245.
Skansén-Saphir U, Andersson J, Björk L, Andersson U. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 1994;24:916–922.
Shimozato T, Iwata M, Tamura N. Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun 1990;58:1384–1390.
Amran D, Renz H, Lack G, Bradley K, Gelfand E. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunpathol 1994;73:180–186.
Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993;92:2533–2539.
Pilz G, Fateh-Moghadam S, Viell B, et al. Supplemental immunoglobulin therapy in sepsis and septic shock-comparison of mortality under treatment with polyvalent i.v. immunoglobulin versus placebo. Protocol of a multicenter, randomized, prospective, double-blind trial. Theor Surg 1993;8:61–83.
Dominioni L, Dionigi R, Zanello M, et al. Effects of highdose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991;126:236–240.
Cafiero F, Gipponi M, Bonalumi U, Piccardo A, Sguotti C, Corbetta G. Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: results of a randomized, multicenter clinical trial. Surgery 1992;112:24–31.
The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with corelipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992;327:234–240.
Pilz G, Kreuzer E, Kääb S, Appel R, Werdan K. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identi~ed high-risk patients. Chest 1994;105:76–82 (errata in 105:1924).
Petros AJ, Marshall JC, van Saene HKF. Should morbidity replace mortality as an endpoint for clinical trials in intensive care? Lancet 1995;345:369–371.
Knaus WA, Wagner DP, Zimmerman JE, Draper EA. Variations in mortality and length of stay in intensive care units. Ann Intern Med 1993;118:753–761.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818–829.
Pilz G, Appel R, Kreuzer E, Werdan K. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest 1997;111:419–426.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pilz, G. Polyvalent Immunoglobulin. Sepsis 1, 15–16 (1997). https://doi.org/10.1023/A:1009798831525
Issue Date:
DOI: https://doi.org/10.1023/A:1009798831525